Professionals deliberate the progression of Immuno-Oncology combinations while also engaging in conversations regarding the issue of immunotherapy resistance.
By Deena Beasley (Reuters) - Mirati Therapeutics Inc's experimental drug that targets a specific genetic mutation helped about one third of a small su.